10:11 AM EST - Theratechnologies Inc. : Announced that it obtained from the European Medicines Agency an additional month to address new questions received yesterday in regard to the establishment of a post-approval registry to gather long-term data on patients taking Trogarzo® (ibalizumab) in Europe. Theratechnologies will submit responses to the EMA by the end of June. The Committee for Medicinal Products for Human Use will then have 30 days to provide a recommendation to the European Union regarding the approval for the commercialization of Trogarzo® in Europe. Theratechnologies Inc.
shares T.TH are trading down $0.03 at $5.93.
